censavudine
Sign in to saveCensavudine (INN; development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
Chemical data
- Formula
- C12H12N2O4
- Molecular weight
- 248.23 g/mol
- IUPAC name
- 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
via PubChem
Article
2 sectionsContents
- Renaming
- References
Censavudine (INN; development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
==Renaming== Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir, etc.).